Do analysts recommend CMMB or OKYO?

OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 310.63%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 OKYO Pharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, CMMB or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is CMMB or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% OKYO Pharma N/A N/A N/A

Do analysts rate CMMB or PLRX?

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 177.78%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Pliant Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Is CMMB or PLRX more profitable?

Pliant Therapeutics' return on equity of -52.17% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% Pliant Therapeutics N/A -52.17% -40.46%

Do analysts prefer APLM or CMMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has better earnings & valuation, APLM or CMMB?

Chemomab Therapeutics has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.65 -$10.94M N/A N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A

Is APLM or CMMB more profitable?

Apollomics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Chemomab Therapeutics N/A -92.14% -82.05%

Do analysts rate CMMB or RNTX?

Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 701.71%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Rein Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation & earnings, CMMB or RNTX?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is CMMB or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% Rein Therapeutics N/A N/A -63.69%

Do analysts rate CMMB or XBIT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, CMMB or XBIT?

XBiotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A XBiotech N/A N/A -$45.54M -$1.48 N/A

Is CMMB or XBIT more profitable?

XBiotech's return on equity of -31.62% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% XBiotech N/A -31.62% -30.29%

Chemomab Therapeutics (CMMB) Competitors

$2.16 -0.04 (-1.82%)

Closing price 04:00 PM Eastern

Extended Trading

$2.17 +0.01 (+0.69%)

As of 07:30 PM Eastern

Compare

CMMB vs. OKYO, PLRX, APLM, RNTX, and XBIT

Should you buy Chemomab Therapeutics stock or one of its competitors? Chemomab Therapeutics's main competitors and comparable companies include OKYO Pharma (OKYO), Pliant Therapeutics (PLRX), Apollomics (APLM), Rein Therapeutics (RNTX), and XBiotech (XBIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Chemomab Therapeutics compare to OKYO Pharma?

Chemomab Therapeutics (NASDAQ:CMMB) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

OKYO Pharma has a consensus price target of $5.67, suggesting a potential upside of 310.63%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
OKYO Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Chemomab Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.03, suggesting that its stock price is 97% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

OKYO Pharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
OKYO Pharma	N/A	N/A	N/A

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.82 beat OKYO Pharma's score of 1.79 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
OKYO Pharma	Very Positive

Summary

OKYO Pharma beats Chemomab Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Pliant Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Chemomab Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
Pliant Therapeutics	$1.58M	42.33	-$149.34M	-$1.49	N/A

Chemomab Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Pliant Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Pliant Therapeutics' return on equity of -52.17% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
Pliant Therapeutics	N/A	-52.17%	-40.46%

Pliant Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 177.78%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Pliant Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Pliant Therapeutics had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for Pliant Therapeutics and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.82 beat Pliant Therapeutics' score of 0.89 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Pliant Therapeutics	Positive

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Pliant Therapeutics beats Chemomab Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLM) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Apollomics and Apollomics both had 1 articles in the media. Apollomics' average media sentiment score of 1.82 equaled Chemomab Therapeutics'average media sentiment score.

Company	Overall Sentiment
Apollomics	Very Positive
Chemomab Therapeutics	Very Positive

19.1% of Apollomics shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Chemomab Therapeutics has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.65	-$10.94M	N/A	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

Apollomics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Chemomab Therapeutics	N/A	-92.14%	-82.05%

Summary

Apollomics and Chemomab Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Rein Therapeutics?

Chemomab Therapeutics (NASDAQ:CMMB) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Rein Therapeutics' return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
Rein Therapeutics	N/A	N/A	-63.69%

Rein Therapeutics has a consensus target price of $6.00, indicating a potential upside of 701.71%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 1 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.82 beat Rein Therapeutics' score of 1.79 indicating that Chemomab Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
Rein Therapeutics	Very Positive

Chemomab Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market.

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rein Therapeutics beats Chemomab Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Chemomab Therapeutics compare to XBiotech?

Chemomab Therapeutics (NASDAQ:CMMB) and XBiotech (NASDAQ:XBIT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

In the previous week, XBiotech had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 2 mentions for XBiotech and 1 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 1.82 equaled XBiotech'saverage media sentiment score.

Company	Overall Sentiment
Chemomab Therapeutics	Very Positive
XBiotech	Very Positive

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 30.8% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

XBiotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A

Chemomab Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

XBiotech's return on equity of -31.62% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
XBiotech	N/A	-31.62%	-30.29%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XBiotech beats Chemomab Therapeutics on 7 of the 10 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.94M	$3.93B	$7.29B	$13.10B
Dividend Yield	N/A	3.63%	2.52%	13.51%
P/E Ratio	-1.01	8.30	213.99	21.16
Price / Sales	N/A	1,331.56	618.37	86.16
Price / Cash	N/A	118.05	79.23	52.93
Price / Book	1.08	15.28	10.43	6.30
Net Income	-$8.99M	-$22.86M	$3.49B	$359.77M
7 Day Performance	-17.24%	-2.94%	-1.25%	-0.17%
1 Month Performance	-6.09%	-8.97%	-4.51%	-4.06%
1 Year Performance	-13.60%	31.46%	16.42%	6.09%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	1.3822 of 5 stars	$2.16 -1.8%	N/A	-15.4%	$15.94M	N/A	N/A	12	Positive News
OKYO OKYO Pharma	3.1332 of 5 stars	$1.35 flat	$5.67 +319.8%	-34.6%	$70.90M	N/A	N/A	5
PLRX Pliant Therapeutics	1.8803 of 5 stars	$1.12 -2.2%	$3.00 +169.1%	-21.9%	$69.29M	$1.58M	N/A	49
APLM Apollomics	2.6451 of 5 stars	$23.75 -0.7%	N/A	+25.9%	$69.11M	$8.50M	N/A	15	Positive News Gap Up
RNTX Rein Therapeutics	2.9581 of 5 stars	$0.79 -0.1%	$6.00 +655.7%	-37.5%	$68.50M	N/A	N/A	10	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. OKYO, PLRX, APLM, RNTX, and XBIT

How does Chemomab Therapeutics compare to OKYO Pharma?

Summary

How does Chemomab Therapeutics compare to Pliant Therapeutics?

Summary

How does Chemomab Therapeutics compare to Apollomics?

Summary

How does Chemomab Therapeutics compare to Rein Therapeutics?

Summary

How does Chemomab Therapeutics compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. OKYO, PLRX, APLM, RNTX, and XBIT

How does Chemomab Therapeutics compare to OKYO Pharma?

Do analysts recommend CMMB or OKYO?

Which has more risk & volatility, CMMB or OKYO?

Which has better valuation and earnings, CMMB or OKYO?

Is CMMB or OKYO more profitable?

Do institutionals and insiders hold more shares of CMMB or OKYO?

Does the media refer more to CMMB or OKYO?

Summary

How does Chemomab Therapeutics compare to Pliant Therapeutics?

Which has better valuation & earnings, CMMB or PLRX?

Which has more risk & volatility, CMMB or PLRX?

Is CMMB or PLRX more profitable?

Do analysts rate CMMB or PLRX?

Does the media refer more to CMMB or PLRX?

Do institutionals & insiders hold more shares of CMMB or PLRX?

Summary

How does Chemomab Therapeutics compare to Apollomics?

Does the media favor APLM or CMMB?

Do insiders & institutionals have more ownership in APLM or CMMB?

Which has more volatility and risk, APLM or CMMB?

Do analysts prefer APLM or CMMB?

Which has better earnings & valuation, APLM or CMMB?

Is APLM or CMMB more profitable?

Summary

How does Chemomab Therapeutics compare to Rein Therapeutics?

Is CMMB or RNTX more profitable?

Do analysts rate CMMB or RNTX?

Does the media refer more to CMMB or RNTX?

Which has more risk and volatility, CMMB or RNTX?

Which has higher valuation & earnings, CMMB or RNTX?

Do institutionals and insiders believe in CMMB or RNTX?

Summary

How does Chemomab Therapeutics compare to XBiotech?

Does the media refer more to CMMB or XBIT?

Do institutionals & insiders hold more shares of CMMB or XBIT?

Which has stronger valuation & earnings, CMMB or XBIT?

Which has more risk & volatility, CMMB or XBIT?

Is CMMB or XBIT more profitable?

Do analysts rate CMMB or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools